查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424044

胜□和寡核甘酸 CDMO 市场、份额、规模、趋势、行业分析报告：按产品、按服务、按最终用户、按地区、按细分市场、预测，2024-2032 年

Peptide and Oligonucleotide CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Peptides, Oligonucleotides); By Service; By End User; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，预计到2032年，全球胜□和寡核甘酸CDMO市场规模将达到46.4657亿美元。 该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

胜□和寡核甘酸 CDMO 在胜□和寡核甘酸的复杂合成中提供高度专业的专业知识并保证精度。 CDMO 凭藉优化的流程和规模经济提供具有成本效益的解决方案。 我们最先进的工厂遵循严格的品质标准和法规合规性，并配备先进的技术。 製造的可扩展性允许灵活适应药物开发不同阶段的不同需求。

胜□和寡核甘酸合约开发涉及客户和 CDMO 之间的密切合作。 在专案规划阶段，双方彻底确定目标、范围和进度，并全面了解客户的需求。 后续阶段包括生物分子阵列的复杂设计和最佳化、严格的可扩展性製程开发以及有效分析方法的建立。 在整个製造过程中严格采用符合监管合规标准的品质控制措施。 技术转移、详细的专案完成报告以及持续改进的举措凸显了我们为这些关键生物分子提供高品质、可重复的製造流程的承诺。

胜□和寡核甘酸 CDMO 製造组织透过提供客製化的合成解决方案为研究机构服务。 这些公司在各种应用领域拥有专业知识，包括药物发现和生物标记开发。 研究机构受惠于 CDMO 推动的无缝放大流程，确保分子的持续供应。 CDMO利用尖端技术，为研究机构提供精密实验的尖端方法。

对法规遵循的支持提高了研究计画的可信度，尤其是转化应用。 合作伙伴关係促进协同效应，CDMO 为研究活动提供技术见解和创新解决方案。 分析服务确保合成分子的可靠性，灵活的服务模式适应动态专案的需求。 专案设计期间的咨询优化了合成策略，我们对及时交付和成本效率的承诺确保了向研究机构持续供应材料。

胜□和寡核甘酸 CDMO 市场报告亮点

2023年，由于生物製药应用的增加、诊断的进步和治疗的进步，胜□领域占据了很大的市场份额。

2023 年，由于外包专业知识、客製化生产和成本效率，合约製造业占据了重要的市场份额。

2023 年，由于治疗开发和简化开发流程的专业服务需求不断增长，生物製药公司部门占据了重要的市场收入份额。

2023 年，由于个人化医疗需求增加、研发活动增加和技术进步，北美地区占据了最大的收入份额。

市场竞争激烈，市场参与者遍布全球，包括 Bachem Group、CordenPharma、Creative Peptides、EUROAPI、Merck KGaA 和 PolyPeptide Group。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第四章全球多胜□与寡核甘酸 CDMO 市场洞察

  • 胜□和寡核甘酸 CDMO 市场 - 最终用户快照
  • 多□和寡核甘酸 CDMO 市场动态
    • 推动者和机会
      • 对智慧型装置连接和无缝整合的需求日益增长
      • 随着全球环保意识的增强和对永续产品的需求，环保型胜□和寡核甘酸 CDMO 正在快速成长。
    • 抑制因素和挑战
      • 胜□和寡核甘酸 CDMO 的高成本限制了市场成长
  • PESTEL 分析
  • 胜□和寡核甘酸 CDMO 市场的最终用户趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第五章全球胜□与寡核甘酸 CDMO 市场（按产品）

  • 主要发现
  • 简介
  • 胜□
  • 寡核甘酸

第 6 章全球胜□和寡核甘酸 CDMO 市场（按服务）

  • 主要发现
  • 简介
  • 合约开发
  • 合约製造

第 7 章全球胜□与寡核甘酸 CDMO 市场（依最终使用者）

  • 主要发现
  • 简介
  • 生物製药公司
  • 製药公司
  • 研究院
  • 学术和政府机构
  • 其他

第 8 章全球胜□与寡核甘酸 CDMO 市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年按地区划分的胜□和寡核甘酸 CDMO 市场评估
  • 胜□和寡核甘酸 CDMO 市场 - 北美
    • 北美：胜□和寡核甘酸 CDMO 市场（按产品），2019-2032 年
    • 北美：胜□和寡核甘酸 CDMO 市场，按最终用户划分，2019-2032 年
    • 北美：2019-2032 年胜□和寡核甘酸 CDMO 市场（按服务划分）
    • 胜□和寡核甘酸 CDMO 市场 - 美国
    • 胜□和寡核甘酸 CDMO 市场 - 加拿大
  • 胜□和寡核甘酸 CDMO 市场 - 欧洲
    • 欧洲：胜□和寡核甘酸 CDMO 市场（按产品），2019-2032 年
    • 欧洲：胜□和寡核甘酸 CDMO 市场，按最终用户划分，2019-2032 年
    • 欧洲：胜□和寡核甘酸 CDMO 市场，按服务分类，2019-2032 年
    • 胜□与寡核甘酸 CDMO 市场 - 英国
    • 胜□与寡核甘酸 CDMO 市场 - 法国
    • 胜□与寡核甘酸 CDMO 市场 - 德国
    • 胜□和寡核甘酸 CDMO 市场 - 义大利
    • 多胜□与寡核甘酸 CDMO 市场 - 西班牙
    • 胜□和寡核甘酸 CDMO 市场 - 荷兰
    • 胜□和寡核甘酸 CDMO 市场 - 俄罗斯
  • 胜□和寡核甘酸 CDMO 市场 - 亚太地区
    • 亚太地区：胜□和寡核甘酸 CDMO 市场（按产品），2019-2032 年
    • 亚太地区：胜□和寡核甘酸 CDMO 市场，按最终用户划分，2019-2032 年
    • 亚太地区：胜□和寡核甘酸 CDMO 市场，按服务划分，2019-2032 年
    • 多□和寡核甘酸 CDMO 市场 - 中国
    • 胜□和寡核甘酸 CDMO 市场 - 印度
    • 胜□和寡核甘酸 CDMO 市场 - 马来西亚
    • 胜□与寡核甘酸 CDMO 市场 - 日本
    • 多□和寡核甘酸 CDMO 市场 - 印度尼西亚
    • 胜□和寡核甘酸 CDMO 市场 - 韩国
  • 多□和寡核甘酸 CDMO 市场 - 中东和非洲
    • 中东和非洲：胜□和寡核甘酸 CDMO 市场（按产品），2019-2032 年
    • 中东和非洲：胜□和寡核甘酸 CDMO 市场，按最终用户划分，2019-2032 年
    • 中东和非洲：胜□和寡核甘酸 CDMO 市场，按服务划分，2019-2032 年
    • 多□和寡核甘酸 CDMO 市场 - 沙乌地阿拉伯
    • 胜□和寡核甘酸 CDMO 市场 - 阿联酋
    • 胜□和寡核甘酸 CDMO 市场 - 以色列
    • 胜□和寡核甘酸 CDMO 市场 - 南非
  • 胜□与寡核甘酸 CDMO 市场 - 拉丁美洲
    • 拉丁美洲：胜□和寡核甘酸 CDMO 市场（按产品），2019-2032 年
    • 拉丁美洲：胜□和寡核甘酸 CDMO 市场，按最终用户划分，2019-2032 年
    • 拉丁美洲：胜□和寡核甘酸 CDMO 市场，按服务划分，2019-2032 年
    • 胜□和寡核甘酸 CDMO 市场 - 墨西哥
    • 胜□和寡核甘酸 CDMO 市场 - 巴西
    • 胜□和寡核甘酸 CDMO 市场 - 阿根廷

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第十章公司简介

  • Aurigene Pharmaceutical Services Ltd.
  • Bachem Group
  • CordenPharma
  • Creative Peptides
  • Curia Global, Inc.
  • EUROAPI
  • Genscript Biotech Corporation
  • Lonza Group
  • Merck KGaA
  • PolyPeptide Group
  • Senn Chemicals AG
  • STA Pharmaceutical Co. Ltd.
  • Sylentis, S.A.
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec
Product Code: PM4342

The global Peptide and Oligonucleotide CDMO market size is expected to reach USD 4,646.57 million by 2032, according to a new study by Polaris Market Research. The report "Peptide and Oligonucleotide CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Peptides, Oligonucleotides); By Service; By End User; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Peptide and Oligonucleotide Contract Development and Manufacturing Organizations (CDMOs) offer highly specialized expertise in the intricate synthesis of peptides and oligonucleotides, ensuring precision. CDMOs offer cost-efficient solutions through optimized processes and economies of scale. Their state-of-the-art facilities adhere to rigorous quality standards and regulatory compliance, equipped with advanced technologies. Scalability in manufacturing allows for flexible adaptation to varying demands during different drug development phases.

Initiating the contract development for peptides and oligonucleotides involves a thorough collaborative endeavor between clients and CDMOs. In the project planning phase, both parties meticulously define objectives, scope, and timelines, ensuring a comprehensive understanding of client requirements. Subsequent stages encompass the intricate design and optimization of biomolecular sequences, rigorous process development for scalability, and the establishment of validated analytical methods. Quality control measures, aligned with regulatory compliance standards, are meticulously applied throughout manufacturing. Technology transfer, detailed project completion reports, and ongoing initiatives for continuous improvement underline the commitment to delivering high-quality, reproducible manufacturing processes for these essential biomolecules.

Peptide and oligonucleotide contract development and manufacturing organizations cater to research institutes by delivering tailored synthesis solutions. These entities bring specialized expertise across diverse applications, including drug discovery and biomarker development. Research institutes benefit from seamless scale-up processes facilitated by CDMOs, ensuring consistent molecule supply. CDMOs leverage state-of-the-art technologies, providing research institutions access to cutting-edge methodologies for precise experimentation.

Regulatory compliance support enhances the credibility of research projects, especially those with translational applications. Collaborative partnerships foster synergy, with CDMOs contributing technical insights and innovative solutions to research endeavors. Analytical services ensure the reliability of synthesized molecules, and flexible service models accommodate dynamic project needs. Consultation during project design optimizes synthesis strategies, and a commitment to timely delivery and cost efficiency ensures uninterrupted material supply for research institutes.

Peptide and Oligonucleotide CDMO Market Report Highlights

In 2023, the peptides segment accounted for substantial market share owing to rise in biopharmaceutical applications, diagnostic advancements, and therapeutic advancements.

In 2023, contract manufacturing segment accounted for significant market share due to outsourcing expertise, customized production, and cost efficiency.

In 2023, the biopharmaceutical companies segment held significant market revenue share due to greater demand for specialized services for therapeutic development, and streamlining of development processes.

In 2023, North America accounted for the largest revenue share due to rise in demand for personalized medicine, increased R&D activities, and technological advancements.

The market is highly competitive owing to the existence of market players with a global presence, including Bachem Group, CordenPharma, Creative Peptides, EUROAPI, Merck KGaA, and PolyPeptide Group among others.

Polaris Market Research has segmented the Peptide and Oligonucleotide CDMO market report based on product, service, end user, and region:

Peptide and Oligonucleotide CDMO, Product Outlook (Revenue - USD Million, 2019 - 2032)

  • Peptides
  • Oligonucleotides

Peptide and Oligonucleotide CDMO, Service Outlook (Revenue - USD Million, 2019 - 2032)

  • Contract Development
  • Contract Manufacturing

Peptide and Oligonucleotide CDMO, End User Outlook (Revenue - USD Million, 2019 - 2032)

  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Research Institutes
  • Academic and Government Organizations
  • Others

Peptide and Oligonucleotide CDMO, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Peptide and Oligonucleotide CDMO Market Insights

  • 4.1. Peptide and Oligonucleotide CDMO Market - End User Snapshot
  • 4.2. Peptide and Oligonucleotide CDMO Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing need for connectivity and seamless integration with smart devices
      • 4.2.1.2. Rising environmental consciousness and the demand for sustainable products worldwide are driving the growth of eco-friendly Peptide and Oligonucleotide CDMO at rapid pace.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of Peptide and Oligonucleotide CDMO limit the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Peptide and Oligonucleotide CDMO Market End User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Peptide and Oligonucleotide CDMO Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • 5.3. Peptides
    • 5.3.1. Global Peptide and Oligonucleotide CDMO Market, by Peptides, by Region, 2019-2032 (USD Million)
  • 5.4. Oligonucleotides
    • 5.4.1. Global Peptide and Oligonucleotide CDMO Market, by Oligonucleotides, by Region, 2019-2032 (USD Million)

6. Global Peptide and Oligonucleotide CDMO Market, by Service

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 6.3. Contract Development
    • 6.3.1. Global Peptide and Oligonucleotide CDMO Market, by Contract Development, by Region, 2019-2032 (USD Million)
  • 6.4. Contract Manufacturing
    • 6.4.1. Global Peptide and Oligonucleotide CDMO Market, by Contract Manufacturing, by Region, 2019-2032 (USD Million)

7. Global Peptide and Oligonucleotide CDMO Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • 7.3. Biopharmaceutical Companies
    • 7.3.1. Global Peptide and Oligonucleotide CDMO Market, by Biopharmaceutical Companies, By Region, 2019-2032 (USD Million)
  • 7.4. Pharmaceutical Companies
    • 7.4.1. Global Peptide and Oligonucleotide CDMO Market, by Pharmaceutical Companies, By Region, 2019-2032 (USD Million)
  • 7.5. Research Institutes
    • 7.5.1. Global Peptide and Oligonucleotide CDMO Market, by Research Institutes, By Region, 2019-2032 (USD Million)
  • 7.6. Academic and Government Organizations
    • 7.6.1. Global Peptide and Oligonucleotide CDMO Market, by Academic and Government Organizations, By Region, 2019-2032 (USD Million)
  • 7.7. Others
    • 7.7.1. Global Peptide and Oligonucleotide CDMO Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Peptide and Oligonucleotide CDMO Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Peptide and Oligonucleotide CDMO Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Peptide and Oligonucleotide CDMO Market - North America
    • 8.3.1. North America: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.3.2. North America: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.3.3. North America: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.3.4. Peptide and Oligonucleotide CDMO Market - U.S.
      • 8.3.4.1. U.S.: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.3.5. Peptide and Oligonucleotide CDMO Market - Canada
      • 8.3.5.1. Canada: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 8.4. Peptide and Oligonucleotide CDMO Market - Europe
    • 8.4.1. Europe: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.4.3. Europe: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.4. Peptide and Oligonucleotide CDMO Market - UK
      • 8.4.4.1. UK: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.5. Peptide and Oligonucleotide CDMO Market - France
      • 8.4.5.1. France: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.5.3. France: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.6. Peptide and Oligonucleotide CDMO Market - Germany
      • 8.4.6.1. Germany: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.7. Peptide and Oligonucleotide CDMO Market - Italy
      • 8.4.7.1. Italy: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.8. Peptide and Oligonucleotide CDMO Market - Spain
      • 8.4.8.1. Spain: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.9. Peptide and Oligonucleotide CDMO Market - Netherlands
      • 8.4.9.1. Netherlands: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.4.10. Peptide and Oligonucleotide CDMO Market - Russia
      • 8.4.10.1. Russia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 8.5. Peptide and Oligonucleotide CDMO Market - Asia Pacific
    • 8.5.1. Asia Pacific: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.4. Peptide and Oligonucleotide CDMO Market - China
      • 8.5.4.1. China: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.4.3. China: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.5. Peptide and Oligonucleotide CDMO Market - India
      • 8.5.5.1. India: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.5.3. India: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.6. Peptide and Oligonucleotide CDMO Market - Malaysia
      • 8.5.6.1. Malaysia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.7. Peptide and Oligonucleotide CDMO Market - Japan
      • 8.5.7.1. Japan: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.8. Peptide and Oligonucleotide CDMO Market - Indonesia
      • 8.5.8.1. Indonesia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.5.9. Peptide and Oligonucleotide CDMO Market - South Korea
      • 8.5.9.1. South Korea: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 8.6. Peptide and Oligonucleotide CDMO Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.6.4. Peptide and Oligonucleotide CDMO Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.6.5. Peptide and Oligonucleotide CDMO Market - UAE
      • 8.6.5.1. UAE: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.6.6. Peptide and Oligonucleotide CDMO Market - Israel
      • 8.6.6.1. Israel: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.6.7. Peptide and Oligonucleotide CDMO Market - South Africa
      • 8.6.7.1. South Africa: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • 8.7. Peptide and Oligonucleotide CDMO Market - Latin America
    • 8.7.1. Latin America: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.7.4. Peptide and Oligonucleotide CDMO Market - Mexico
      • 8.7.4.1. Mexico: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.7.5. Peptide and Oligonucleotide CDMO Market - Brazil
      • 8.7.5.1. Brazil: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
    • 8.7.6. Peptide and Oligonucleotide CDMO Market - Argentina
      • 8.7.6.1. Argentina: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Aurigene Pharmaceutical Services Ltd.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bachem Group
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. CordenPharma
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Creative Peptides
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Curia Global, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. EUROAPI
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Genscript Biotech Corporation
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Lonza Group
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Merck KGaA
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. PolyPeptide Group
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Senn Chemicals AG
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. STA Pharmaceutical Co. Ltd.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Sylentis, S.A.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Thermo Fisher Scientific Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Wuxi AppTec
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables

  • Table 1 Global Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 2 Global Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 3 Global Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 4 Peptide and Oligonucleotide CDMO Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 6 North America: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 7 North America: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 8 U.S.: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 9 U.S.: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 10 U.S.: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 11 Canada: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 12 Canada: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 13 Canada: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 14 Europe: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 15 Europe: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 16 Europe: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 17 UK: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 18 UK: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 19 UK: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 20 France: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 21 France: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 22 France: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 23 Germany: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 24 Germany: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 25 Germany: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 26 Italy: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 27 Italy: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 28 Italy: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 29 Spain: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 30 Spain: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 31 Spain: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 32 Netherlands: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 33 Netherlands: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 34 Netherlands: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 35 Russia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 36 Russia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 37 Russia: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 41 China: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 42 China: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 43 China: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 44 India: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 45 India: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 46 India: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 47 Malaysia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 48 Malaysia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 49 Malaysia: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 50 Japan: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 51 Japan: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 52 Japan: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 53 Indonesia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 54 Indonesia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 55 Indonesia: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 56 South Korea: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 57 South Korea: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 58 South Korea: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 65 UAE: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 66 UAE: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 67 UAE: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 68 Israel: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 69 Israel: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 70 Israel: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 71 South Africa: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 72 South Africa: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 73 South Africa: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 74 Latin America: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 75 Latin America: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 76 Latin America: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 77 Mexico: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 78 Mexico: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 79 Mexico: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 80 Brazil: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 81 Brazil: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 82 Brazil: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)
  • Table 83 Argentina: Peptide and Oligonucleotide CDMO Market, by Product, 2019-2032 (USD Million)
  • Table 84 Argentina: Peptide and Oligonucleotide CDMO Market, by Service, 2019-2032 (USD Million)
  • Table 85 Argentina: Peptide and Oligonucleotide CDMO Market, by End User, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Peptide and Oligonucleotide CDMO Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Service
  • Figure 7. Global Peptide and Oligonucleotide CDMO Market, by Service, 2022 & 2032 (USD Million)
  • Figure 8. Market by Product
  • Figure 9. Global Peptide and Oligonucleotide CDMO Market, by Product, 2022 & 2032 (USD Million)
  • Figure 10. Market by End User
  • Figure 11. Global Peptide and Oligonucleotide CDMO Market, by End User, 2022 & 2032 (USD Million)
  • Figure 12. Peptide and Oligonucleotide CDMO Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Peptide and Oligonucleotide CDMO Market